acalbrutinib

Acalabrutinib is a targeted cancer therapy that inhibits Bruton’s tyrosine kinase (BTK), an enzyme involved in the growth and survival of certain cancer cells, particularly in blood cancers like chronic lymphocytic leukemia (CLL). By blocking BTK, acalabrutinib disrupts signals that promote cancer cell growth, leading to their death or slowing their proliferation. It is usually taken orally and is designed to be more selective than earlier treatments, potentially reducing side effects. Acalabrutinib offers an effective option for patients with specific blood cancers, especially when other treatments have not worked or are unsuitable.